Antitumor Response to a Codon-Optimized HPV-16 E7/HSP70 Fusion Antigen DNA Vaccine
Hoorieh
Soleimanjahi
Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
author
Hadi
Razavinikoo
Laboratory Science Research Center, Golestan University of Medical Sciences, Gorgan, Iran
author
Fatemeh
Fotouhi
Influenza Research Lab, Department of Virology, Pasteur Institute of Iran, Tehran, Iran
author
Abdollah
Ardebili
Laboratory Science Research Center, Golestan University of Medical Sciences, Gorgan, Iran
author
text
article
2017
eng
Background: Vaccines based on virus-like particles are effective against Human Papilloma Virus (HPV) infection; however, they have not shown a therapeutic effect against HPV-associated diseases. New immunotherapy strategies based on immune responses against tumor antigens can positively affect the clearance of HPV-associated lesions. Objective: To generate two therapeutic fusion DNA vaccines (optimizedE7/mouseHSP70 and wildE7/mouseHSP70) to induce antitumor specific responses in mice models. Methods: Mice were immunized with recombinant DNA vaccines. The splenocytes of immunized mice were collected and lactate dehydrogenase and IFN-γ productions were measured after three injections in order to evaluate cytotoxic T lymphocytes (CTLs) activity. MTT assay was carried out for lymphocyte stimulation. Results: The fusion DNA vaccines, specifically uE7-HSP70, elicited varying levels of IFN-γ and CTLs responses compared to the control group (P<0.05). Furthermore, antitumor response and tumor size reduction in fusion DNA vaccines groups were significantly higher than in the negative control group (P<0.05). Conclusion: It is concluded that our fusion DNA vaccines considerably enhanced specific cellular responses against HPV tumor model. In addition, optimized E7 showed a notable immunogenicity and inhibitory effect on the reduction of tumor size.
Iranian Journal of Immunology
Shiraz Institute for Cancer Research
1735-1383
14
v.
3
no.
2017
180
191
https://iji.sums.ac.ir/article_39308_06a6513856f9ff2890487ea2d125671d.pdf
Rapamycin Inhibits Expansion of Cord Blood Derived NK and T Cell
Monireh
Zare
Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
author
Behnaz
Valipour
Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
author
Seyede Momeneh
Mohammadi
Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
author
Mohammad
Nouri
Department of Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
author
Aliakbar
Movassaghpour
Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
author
Hojjatollah
Nozad Charoudeh
Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
author
text
article
2017
eng
Background: The mammalian target of rapamycin (mTOR) is important in hematopoiesis. Despite the central role of mTOR in regulating the differentiation of immune cells, the effect of mTOR function on cord blood mononuclear cells is yet to be defined. Objectives: To evaluate the effect of mTOR inhibition, using rapamycin on the proliferation and apoptosis of cord blood mononuclear cells, as well as on the B and T cell expansion. Methods: Cord blood mononuclear cells were cultured in the presence of IL-2, IL-7 and IL-15 cytokines and inhibited by rapamycin for 14 days. The harvested cells were evaluated at distinct time points by flow cytometry. Results: The mTOR expression decreased in the presence of rapamycin on day 14. Inhibition of mTOR reduced the proliferation of the cord blood mononuclear cells, yet did not influence apoptosis. Moreover, the number of T and NK cells was significantly reduced in the presence of rapamycin, while no change was observed in the B cell expansion. Conclusion: mTOR signaling plays a crucial part in cord blood derived NK and T cells expansion.
Iranian Journal of Immunology
Shiraz Institute for Cancer Research
1735-1383
14
v.
3
no.
2017
192
199
https://iji.sums.ac.ir/article_39309_c585f948c43dc9f673375f0181d46046.pdf
Polyclonal Antibody against Different Extracellular Subdomains of HER2 Induces Tumor Growth Inhibition in vitro
Reza
Hosseini-Ghatar
Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
author
Tahereh
Soltantoyeh
Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
author
Motahareh
Bahadori
Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
author
Jalal
Khoshnoodi
Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
author
Forough
Golsaz-Shirazi
Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
author
Mahmood
Jeddi-Tehrani
Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
author
Mohammad Mehdi
Amiri
Department of Immunology, School of Public Health, Tehran University of Medical Sciences,Tehran, Iran
author
Fazel
Shokri
Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
author
text
article
2017
eng
Background: Human epidermal growth factor receptor 2 (HER2) has a crucial role in several malignancies. The extracellular domain of HER2 (HER2-ECD) has been extensively employed as an important target in passive and active immunotherapy. Isolated recombinant prokaryotic HER2-ECD subdomains were previously found to be ineffective in inducing anti-tumor antibody response. Objective: To employ recombinant eukaryotic HER2-ECD subdomains to raise anti-HER2 antibodies and determine their anti-tumor activity in vitro. Methods: Two paired subdomains of HER2-ECD (DI+II and DIII+IV), representing Pertuzumab and Trastuzumab binding domains, respectively, along with the full extracellular domain of HER2 were generated in CHO-K1 cells. Polyclonal antibodies were raised against these subdomains and characterized using ELISA, flow cytometry, and immunoblot and their anti-tumor activity was assessed by XTT assay. The cross-reactivity of these antibodies was specified along with other members of the human HER family. Results: Similar to Trastuzumab and anti-HER2-ECD antibody, anti-DI+II and DIII+IV polyclonal antibodies reacted with recombinant HER2-ECD and native HER2 expressed on tumor cells. These two polyclonal antibodies were able to inhibit the binding of Pertuzumab and Trastuzumab to HER2, respectively, and did not cross-react with other members of HER family. These antibodies were able to inhibit tumor cell growth in vitro, similar to Trastuzumab. Conclusion: The high immunogenicity of human HER2 DI+II and DIII+IV subdomains in rabbits and the tumor inhibitory activity of the purified specific antibodies imply that they might be suitable for active immunotherapy in formulation with appropriate adjuvants and in combination with other HER2 specific therapeutics.
Iranian Journal of Immunology
Shiraz Institute for Cancer Research
1735-1383
14
v.
3
no.
2017
200
214
https://iji.sums.ac.ir/article_39310_1cb10af0b5b5e8408a25c82d7c7ea6ff.pdf
Reduced IFN-γ Production in Chronic Brucellosis Patients
Ehsanollah
Ghaznavi-Rad
Molecular and Medicine Research Center (MMRC), Department of Microbiology and Immunology, Arak University of Medical Sciences, Arak, Iran
author
Khadijeh
Khosravi
Department of Microbiology and Immunology, Arak University of Medical Sciences, Arak, Iran
author
Nader
Zarinfar
Department of Infection diseases and tropical medicine, School of Medicine, Arak University of Medical Sciences, Arak, Iran
author
Ghasem
Mosayebi
Molecular and Medicine Research Center (MMRC), Department of Microbiology and Immunology, Arak University of Medical Sciences, Arak, Iran
author
text
article
2017
eng
Background: Brucella is a well-known intracellular bacterium entailing acute and chronic illnesses in humans and domestic animals. The infection chronicity may be affected by the cell-mediated immunity and cytokine patterns. Objective: To evaluate the patterns of T-helper cytokines in patients suffering from chronic and acute brucellosis. Methods: In this cross-sectional study, 22 individuals with acute brucellosis, 21 individuals with chronic brucellosis, and 21 healthy individuals with the same genetic background were recruited from October 2015 to April 2016. Peripheral lymphocytes were isolated and stimulated by phytohemagglutinin (PHA) and brucella antigen in cell culture. The lymphocyte proliferation was detected by MTT assay. After collecting the supernatants, and through the use of ELISA method, we quantified the interferon gamma (IFN-γ), interleukin (IL)-5, IL-17 and transforming growth factor–beta (TGF-β). Results: Patients with chronic brucellosis had a lower level antigen-specific stimulation index compared to those suffering from acute brucellosis (p=0.0001). Cases with chronic brucellosis had a lower level of IFN-γ compared to cases with acute brucellosis (p=0.001). Finally, patients with chronic brucellosis had higher levels of IL-5 and TGF-β in comparison with the acute group (p=0.01 and p=0.04, respectively).Conclusion: Chronic brucellosis reduces lymphocyte proliferation and TH1 cytokine secretion, but it enhances IL- 5 and TGF-β production. Polarizing the immune responses plays a crucial part in the progression and development of chronic diseases.
Iranian Journal of Immunology
Shiraz Institute for Cancer Research
1735-1383
14
v.
3
no.
2017
215
222
https://iji.sums.ac.ir/article_39311_511bb95fda248191fa55853be872e02a.pdf
Association of Human Leukocyte Antigens Class I & II with Graves’ Disease in Iranian Population
Zahra
Mehraji
Department of Cellular and Molecular Biology, Kish International Campus, University of Tehran, Kish Island, Iran
author
Ali
Farazmand
Department of Cellular and Molecular Biology, Faculty of Science, University of Tehran, Tehran, Iran
author
Alireza
Esteghamati
Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
author
Sina
Noshad
Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
author
Maryam
Sadr
Molecular Immunology Research Center and Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
author
Somayeh
Amirzargar
Molecular Immunology Research Center and Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
author
Mir Saeed
Yekaninejad
Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
author
Aliakbar
Amirzargar
Molecular Immunology Research Center and Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
author
text
article
2017
eng
Background: Graves’ disease (GD), a highly rampant autoimmune disorder of the thyroid gland, is responsible for 60-80% of the clinical cases of hyperthyroidism. Over the past decades, genetic association studies have identified several GD susceptibility loci in CTLA-4, TSHR and major histocompatibility complex regions. The information on the association between the human leukocyte antigens (HLA) and GD among Iranians is scarce. Objective: To identify HLA polymorphisms that might confer susceptibility or protect against GD. Methods: Eighty unrelated patients with a confirmed diagnosis of GD were included in the case group. The control group consisted of 180 unrelated healthy individuals with normal thyroid function tests. The polymerase chain reaction with sequence specific primers (PCR-SSP) method was used for HLA typing. Results: Frequencies of HLA-A*68 (15.6% vs. 4.2%, p=0.004) and B*08 (8.8% vs. 2.5, p=0.030) were significantly higher in patients with GD compared with healthy controls. No patients with GD had HLA-A*33, whereas it was found in 7.0% of the controls (p=0.011). HLA-DQB1*0201 was significantly less frequent among patients with GD (15.6% vs. 26.8%, p=0.040). Additionally, patients with GD were significantly less bound to have HLA-DQA1*0201 (6.2% vs. 15.1%, p=0.045). Concerning allelic distributions, no noticeable difference was found between GD patients with and without Graves’ ophthalmopathy (p>0.05 in all cases). Conclusion: In the Iranian population, HLA-A*68 and -B*08 confer susceptibility to GD, whereas HLA-A*33, -DQB1*0201, and -DQA1*0201 appear to have protective roles.
Iranian Journal of Immunology
Shiraz Institute for Cancer Research
1735-1383
14
v.
3
no.
2017
223
230
https://iji.sums.ac.ir/article_39312_ecf2072a42365f8d637fb36506c882c2.pdf
Combination of Myelin Basic Protein Gene Polymorphisms with HLA-DRB1*1501 in Iranian Patients with Multiple Sclerosis
Parham
Nejati
Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran
author
Marzieh
Attar
Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran
author
Maryam
Rahimian
Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran
author
Davood
Fathi
Department of Neurology, 5th Azar University Hospital, Golestan University of Medical Sciences, Gorgan, Iran
author
Majid
Shahbazi
Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran
author
text
article
2017
eng
Background: Multiple sclerosis (MS), as a multifactorial autoimmune disease with complex genetic basis, causes demyelination in the central nervous system via cytokine responses to myelin antigens. Myelin basic protein (MBP) is the main protein component of the myelin sheath. HLA-DRB (human leukocyte antigen-DR beta) alleles, particularly HLA-DRB1*1501, may be of significance in the pathogenesis of MS. Objective: To examine the association of HLA-DRB1*1501 alleles and MBP VNTR (variable number tandem repeat) polymorphism with the MS susceptibility in Iranian population. Methods: Genomic DNA was extracted from peripheral blood. The alleles were determined by the Polymerase Chain Reaction (PCR) method in 259 MS patients and 312 healthy control individuals and analyses were carried out using Fisher's exact test. Results: The frequencies of MBP VNTR genotypes (AA, AB and BB) were 47%, 42% and 11% among patients, and 45%, 43% and 12% in control subjects, respectively. HLA-DRB1*1501 allele was more frequent among patients than healthy individuals (OR=1.65, P=0.0045). The frequency of allele A and genotype A/A was significantly higher among HLA-DRB1*1501 positive patients (61% and 32%) than controls (46% and 19%) (OR=1.88, P=0.0013; A/A vs. B/B: OR=5.09, P=0.0004). The two-locus analysis of the interaction between the MBP VNTR polymorphism and the HLA-DRB1 allele showed that the HLADRB1* 1501/A haplotype was more frequent among MS patients than the healthy controls. Conclusion: The interaction between the HLA-DRB1*1501 allele and MBP gene may be considered as a predisposing factor in the development and pathogenesis of MS in the case of gene-gene interaction.
Iranian Journal of Immunology
Shiraz Institute for Cancer Research
1735-1383
14
v.
3
no.
2017
231
239
https://iji.sums.ac.ir/article_39313_9f6f8667fd2960b6111b69fa9611ce11.pdf
Human Leukocyte Antigen Class I and II Variants in Yemeni Patients with Chronic Renal Failure
Mogahid Yahi'a
Nassar
Department of Clinical Pathology, Faculty of Medicine and Health Sciences, University of Science and Technology, Sana'a, Yemen
author
Hassan Abdulwahab
Al-Shamahy
Department of Microbiology, Faculty of Medicine and Health Sciences, Sana'a, Yemen
author
Abdullah Saleh
Al-Samawi
Department of Pathology, Faculty of Medicine and Health Sciences, Sana'a, Yemen
author
Nagieb Waza'a
Abu Asba
Urology and Nephrology Center, Al-Thawra General Hospital; Department of Nephrology, Faculty of Medicine and Health Sciences, Sana'a, Yemen
author
Ibrahiem Husain
El-Nono
Urology and Nephrology Center Al-Thawra General Hospital; Department of Urology, Faculty of Medicine and Health Sciences, Sana'a University, Sana'a, Yemen
author
Haitham Abdulwahab
Masood
HLA Typing Unit, Al-Thawra General Hospital, Sana'a, Yemen
author
text
article
2017
eng
Background: Human leukocyte antigens (HLAs) are found to be significant genetic factors concerning the susceptibility of an individual to certain diseases. Objective: To determine the association between variants of class I (A and B) and class II (DRB1) HLA alleles and chronic renal failure (CRF), compared with healthy controls, in Yemen. Methods: A case-control study in the Urology and Nephrology Center at Al-Thawra University Hospital in Sana’a, Yemen was carried out between January 2013 and December 2015 and included 187 CRF patients, and 194 healthy controls visiting the same center for kidney donation. All CRF patients in the study were on haemodialysis. The control group was confirmed to be healthy following a clinical examination by specialist physicians. Among both patients and controls, HLA class I (A and B) and class II (DRB1) HLA typing was carried out by Sequence Specific Primers (SSP) polymerase chain reaction (PCR). Results: There was a significant protective function for HLA-A*30 gene (CRF 9.1% vs. con 16%, p=0.045) against CRF development. There was a high frequency of HLA-A*02, HLA-B*51 and HLA-DRB1*04 alleles in both patients and controls. Conclusion: No HLAs were located to have a significant association with genetic tendency to CRF in the current study population, however, certain HLA alleles, for instance in HLA-A*30, could be considered protective against CRF progress.
Iranian Journal of Immunology
Shiraz Institute for Cancer Research
1735-1383
14
v.
3
no.
2017
240
249
https://iji.sums.ac.ir/article_39314_cb28b3924ae8830f0456fc46a58ac585.pdf
Poly I:C Delivery into J774.1 & RAW264.7 Macrophages Induces Rapid Cell Death
Cheah Wen
Yapp
PAPRSB Institute of Health Sciences, University of Brunei Darussalam, Brunei Darussalam
author
Amal
Widaad Mohaimin
PAPRSB Institute of Health Sciences, University of Brunei Darussalam, Brunei Darussalam
author
Adi
Idris
PAPRSB Institute of Health Sciences, University of Brunei Darussalam, Brunei Darussalam, Menzies Health Institute Queensland, School of Medical Science, Griffith University, Gold Coast, Queensland, Australia
author
text
article
2017
eng
Background: Cytosolic double-stranded RNA (dsRNA) is an important ‘molecular signature’ for the detection of intracellular viral infections. Although intracellular dsRNA is a known potent inducer of apoptosis, the optimal time and dose for the onset of dsRNA-mediated apoptosis have not been studied in detail. Objective: To perform an accurate temporal assessment of the cell death responses in dsRNA-dependent cytotoxicity. Methods: Poly I:C (PIC), a synthetic dsRNA molecule was delivered intracellularly into J774.1 and RAW264.7 murine macrophages via electroporation. Cell viability was measured using the MTT assay and apoptosis was determined by sub-G0/G1 DNA content using flow cytometry. Results: Loss of cell viability was seen as early as 3h post-electroporation of macrophages. A significant increase in the sub-G0/G1 DNA content consistent with apoptosis was observed in PIC-electroporated macrophages as early as 3h post electroporation. Conclusion: Intracellular PIC delivery induces rapid macrophage cell death.
Iranian Journal of Immunology
Shiraz Institute for Cancer Research
1735-1383
14
v.
3
no.
2017
250
256
https://iji.sums.ac.ir/article_39315_5d3384d5a522bb3d77a722f4bac1db2e.pdf